Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Rajneesh Agrawal

Diagnostic Radiology Las Vegas, NV Medical Doctor

NPI 1659319614 CMS profile 119766

2020 Palomino Ln, Ste 100, Las Vegas, NV 89106

Open in the dashboard

General payments

$145,045

454 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Rajneesh Agrawal of Las Vegas, NV is reported in the CMS Open Payments database as having received $145,045 across 454 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 98th percentile of Diagnostic Radiology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $5,243 25
2024 General $6,300 51
2023 General $17,356 62
2022 General $25,762 64
2021 General $47,470 79
2020 General $15,522 68
2019 General $27,392 105

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Rajneesh Agrawal
  • Diagnostic Radiology median
  • Middle half of Diagnostic Radiology
  • National median

In program year 2025, general payments to Rajneesh Agrawal were reported at $5,243. Among 8,325 Diagnostic Radiology profiles paid that year, the median was $112 and the middle half received between $32 and $349.

Show as a table
Year Rajneesh Agrawal Diagnostic Radiology median Middle half National median
2019 $27,392 $108 $29–$318 $163
2020 $15,522 $65 $21–$252 $114
2021 $47,470 $92 $24–$292 $132
2022 $25,762 $104 $29–$294 $149
2023 $17,356 $110 $29–$337 $160
2024 $6,300 $113 $30–$356 $164
2025 $5,243 $112 $32–$349 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Stryker Corporation $78,218 107 payments
  2. Penumbra, Inc. $51,596 197 payments
  3. MicroVention, Inc. $5,708 32 payments
  4. Boston Scientific Corporation $3,396 20 payments
  5. Medtronic, Inc. $3,012 32 payments
  6. Shockwave Medical, Inc $541 5 payments
  7. Medtronic USA, Inc. $490 35 payments
  8. Scientia Vascular $344 1 payment
  9. Sirtex Medical Inc $290 2 payments
  10. Imperative Care, INc $284 4 payments
  11. Other $1,166 19 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $72,880 25 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $30,600 15 payments
  3. Food and Beverage $28,641 361 payments
  4. Travel and Lodging $12,924 53 payments
Products named General payments · program years 2019–2025
  1. SPINEJACK Interventional Spine $26,274 21 payments
  2. SURPASS EVOLVE $23,697 29 payments
  3. Penumbra System Neurointervention $19,975 32 payments
  4. IVS - VERTEBRAL AUGMENTATION PRODUCTS $19,162 16 payments
  5. Penumbra System Neurointervention $16,047 42 payments
  6. SPINEJACK Spine $6,671 8 payments
  7. OPTABLATE $5,591 4 payments
  8. Indigo System $5,230 19 payments
  9. AUTOPLEX $4,252 3 payments
  10. IVAS $4,225 2 payments
  11. Other $37,810 323 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

55

Median for Diagnostic Radiology: 24

Drug cost

$455

Median for Diagnostic Radiology: $190

Branded share of claims

100%

Median for Diagnostic Radiology: 0%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 55 $455

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 1,198 Part D prescribers listed as Diagnostic Radiology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 180 billing codes

Paid by Medicare

$242,047

Of which drugs: $3,183

Medicare patients

1,977

Average age 73

Services billed

13,502

1,073 women, 904 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 59%
Diabetes 47%
Ischemic heart disease 45%
Chronic kidney disease 40%
Heart failure 36%
COPD 34%
Depression 34%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, gadolinium-based magnetic resonance contrast agent, not otherwise specified (nos), per ml A9579 Office 121 2,014 $2,375
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml Q9967 Office 109 7,926 $808

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

454 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Diagnostic Radiology in Nevada

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record